<DOC>
	<DOCNO>NCT02339155</DOCNO>
	<brief_summary>This study , post-marketing commitment Food Drug Administration , design detect effect raxibacumab anthrax vaccine adsorb ( AVA ) immunogenicity healthy volunteer population . This randomized , open-label , parallel group , two arm study compare immunogenicity AVA 4 week first AVA dose , AVA administer alone concomitantly raxibacumab . The study plan enroll approximately 30 534 subject 3 cohort . The total duration study approximately 26 week . The date reflect cohort 1 .</brief_summary>
	<brief_title>Effect Raxibacumab Immunogenicity Anthrax Vaccine Adsorbed</brief_title>
	<detailed_description />
	<mesh_term>Anthrax</mesh_term>
	<mesh_term>Bacterial Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Diphenhydramine</mesh_term>
	<mesh_term>Promethazine</mesh_term>
	<criteria>Healthy determine Investigator medically qualify designee base medical evaluation include medical history , physical examination laboratory test Men woman 18 65 year age Willing able adhere procedure state protocol . Female subject eligible participate pregnant ( confirm negative serum urine human chorionic gonadotrophin ( hCG ) test ) , lactate , least one follow condition applies : Nonreproductive potential define : Premenopausal females one following : Documented tubal ligation , Documented hysteroscopic tubal occlusion procedure followup confirmation bilateral tubal occlusion , Hysterectomy , Documented Bilateral Oophorectomy Postmenopausal define 12 month spontaneous amenorrhea . Females hormone replacement therapy ( HRT ) whose menopausal status doubt require use one highly effective contraception method wish continue HRT study . Otherwise , must discontinue HRT allow confirmation postmenopausal status prior study enrollment . Reproductive potential agrees follow one option list GSK Modified List Highly Effective Methods Avoiding Pregnancy Females Reproductive Potential ( FRP ) , 30 day prior first dose study medication last dose study medication completion followup visit Day 183 ( least five terminal halflives raxibacumab ) . Concurrently participate another clinical study , time study period , subject expose investigational noninvestigational study vaccine/product ( pharmaceutical product device ) . Be member military , laboratory worker , first responder , health care worker , otherwise high risk exposure anthrax . History regular alcohol consumption within 1 month study define : An average weekly intake &gt; 14 drink male &gt; 7 drink female . One drink equivalent 12 g alcohol : 12 ounce ( 360 milliliter [ mL ] ) beer , 5 ounce ( 150 mL ) wine 1.5 ounce ( 45 mL ) 80 proof distil spirit . Female plan become pregnant planning discontinue contraceptive precaution Day 183 study visit . Pregnant ( confirm serum urine hCG test ) lactate female . Alanine aminotransferase ( ALT ) bilirubin &gt; 1.5 x upper limit normal ( ULN ) ( isolated bilirubin &gt; 1.5 x ULN acceptable bilirubin fractionate direct bilirubin &lt; 35 % ) . Current chronic history liver disease , know hepatic biliary abnormality ( exception Gilbert 's syndrome asymptomatic gallstone ) . Any confirm suspect immunosuppressive immunodeficient condition result disease ( e.g. , malignancy , human immunodeficiency virus [ HIV ] infection ) immunosuppressive/cytotoxic therapy ( e.g. , medication use cancer chemotherapy , organ transplantation treat autoimmune disorder ) . Presence hepatitis B surface antigen ( HBsAg ) , positive hepatitis C antibody test result screen within 3 month prior first dose study treatment . A positive prestudy drug/alcohol screen . A positive test HIV antibody . History sensitivity study medication , component thereof ( especially latex aluminium ) history know drug allergy , opinion Investigator GSK Medical Monitor , contraindicate participation . Have previously vaccinate PA. Have antiPA Ab concentration &gt; 2 time low limit quantitation screen . Administration immunoglobulins include trial and/or blood product within 3 month precede first dose study vaccine plan administration study period . Administration longacting immunemodifying drug ( e.g . infliximab ) within six month prior first vaccine dose expect administration time study period . Chronic administration ( define 14 consecutive day ) systemic immunosupressants immunemodifying drug within six month prior first vaccine dose . Inhaled , topical intraarticular corticosteroid allow . Administration plan administration vaccine foreseen study protocol within period start 35 day first dose study vaccine ( ) end 30 day last dose study vaccine . This include type vaccine ( limited ) live , inactivate , subunit vaccine . Influenza vaccine permit Week 8 . Subjects must abstain take prescription nonprescription drug ( include vitamin dietary herbal supplement ) , within 7 day ( 14 day drug potential enzyme inducer ) 5 halflives ( whichever longer ) prior first dose study medication completion followup visit , unless opinion Investigator sponsor medication interfere study . Exposure four new chemical entity within 12 month prior first dose day . Any condition , opinion investigator , prevents subject participate study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Anthrax Vaccine Adsorbed</keyword>
	<keyword>Raxibacumab</keyword>
	<keyword>Immunogenicity</keyword>
</DOC>